T. Fry

Oncology · Nature Medicine · 2005–2019

A researcher in the Science corpus: 7 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom T. Fry trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. S. Jameson
  2. H. Kantarjian

Papers from T. Fry's perspective

Ordered by how strongly the researchers T. Fry trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia (New England Journal of Medicine)
  2. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate… (Journal of Clinical Oncology)
  3. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. (The Lancet Oncology)
  4. IL-7 is critical for homeostatic proliferation and survival of naïve T cells (Proceedings of the National Academy of Sciences of the United States of America)
  5. STAR: ultrafast universal RNA-seq aligner (Bioinform.)
  6. Interleukin (IL)-15 and IL-7 Jointly Regulate Homeostatic Proliferation of Memory Phenotype CD8+ Cells but Are Not Required for Memory Phenotype CD4+ Cells (Journal of Experimental Medicine)
  7. Frequent pathway mutations of splicing machinery in myelodysplasia (Nature)
  8. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia (Nature Genetics)
  9. ESEfinder: a web resource to identify exonic splicing enhancers (Nucleic Acids Res.)
  10. Automatic and quantitative measurement of protein-protein colocalization in live cells. (Biophysical Journal)

Their papers